Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Operating Margin: 2019-2025

Historic Operating Margin for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -1,513.47%.

  • Avidity Biosciences' Operating Margin rose 268747.00% to -1,513.47% in Q3 2025 from the same period last year, while for Sep 2025 it was -2,934.90%, marking a year-over-year increase of 27445.00%. This contributed to the annual value of -3,477.43% for FY2024, which is 101302.00% down from last year.
  • Latest data reveals that Avidity Biosciences reported Operating Margin of -1,513.47% as of Q3 2025, which was up 65.98% from -4,448.71% recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Operating Margin registered a high of -882.29% during Q1 2021, and its lowest value of -8,360.90% during Q1 2025.
  • In the last 3 years, Avidity Biosciences' Operating Margin had a median value of -3,043.46% in 2023 and averaged -3,526.22%.
  • Examining YoY changes over the last 5 years, Avidity Biosciences' Operating Margin showed a top increase of 268,747bps in 2025 and a maximum decrease of 618,233bps in 2025.
  • Over the past 5 years, Avidity Biosciences' Operating Margin (Quarterly) stood at -2,081.37% in 2021, then skyrocketed by 15,920bps to -1,922.17% in 2022, then crashed by 112,128bps to -3,043.46% in 2023, then plummeted by 102,617bps to -4,069.63% in 2024, then surged by 268,747bps to -1,513.47% in 2025.
  • Its Operating Margin was -1,513.47% in Q3 2025, compared to -4,448.71% in Q2 2025 and -8,360.90% in Q1 2025.